Moreover, the MLLT4 gene not only has been illustrated to participate in the RAS signaling pathway as the factor of cell junctions related to progression of GMB but also been demonstrated as a crucial predictor to efficiently classify prognostic categories of GBM patients (Yang et al. 2019 in Supplementary notes T1). The gene discussed is AFDN; the disease is glioblastoma.